• Hai-Feng Gu, Ling-Jia Gu, Yue Wu, Xiao-Hong Zhao, Qing Zhang, Zhe-Rong Xu, and Yun-Mei Yang.
• From the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou (H-FG, YW, X-HZ, QZ, Z-RX, Y-MY); and Taizhou First People's Hospital, TaiZhou, China (L-JG).
• Medicine (Baltimore). 2015 Nov 1; 94 (44): e1674e1674.

AbstractThe purpose of this study was to perform a meta-analysis to examine the efficacy and safety of denosumab in postmenopausal women with osteoporosis.Medline, Cochrane Library, EMBASE, and Google Scholar databases were searched until October 30, 2014 using combinations of the following search terms: osteoporosis, postmenopause, postmenopausal, women, denosumab. The primary outcome was bone mineral density (BMD) change, and secondary outcomes were change in the bone turnover markers β-isomerized carboxy-terminal cross-linking telopeptide of type I collagen (CTX) and serum procollagen type I amino-terminal propeptide (P1NP), and adverse events.Patients treated with denosumab had significantly increased BMD of the lumbar spine (7.58%), total hip (4.86%), and distal third of the radius (2.92%) than those treated with placebo (all, P < 0.001). Patients treated with denosumab had a significant decrease of CTX (-66.16%) and P1NP (-64.65%) as compared with those treated with placebo (both, P < 0.001). Adverse events were similar between the 2 groups (pooled odds ratio = 1.04, P = 0.625).Denosumab increases BMD and decreases markers of bone turnover in postmenopausal women with osteoporosis, and is not associated with significant side-effects.

11 keywords...

hide…